Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

NCT03044353 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped Change in benefit/risk profile

Conditions

Amyloidosis

Interventions

DRUG: GSK2315698 (CPHPC)
BIOLOGICAL: GSK2398852 (anti-SAP mAb)

Sponsor

GlaxoSmithKline